Zimmer Biomet Beats Q3, Raises Guidance

The orthopedic device maker reported third-quarter earnings above analyst estimates and lifted its full-year fiscal 2026 outlook.

Updated on Nov. 4, 2026 in Corporate Finance

Photograph of a polished metal orthopedic implant component resting on a stainless steel surgical tray in a bright, clean manufacturing room. — Zimmer Biomet beat third-quarter earnings estimates on Tuesday, posting $1.90 per share and $2.063 billion in sales, and raised its fiscal 2026 profit outlook to $8.50-$8.60. AI Illustration. Upload story photo >

Zimmer Biomet reported third-quarter adjusted earnings of $1.90 per share, above estimates of $1.88, and quarterly sales of $2.063 billion, above estimates of $2.040 billion. The company also raised its fiscal 2026 adjusted earnings guidance to $8.50-$8.60 per share.

Why it matters

The results show growth in hips, SET businesses, and technology and data offsetting pressure in knees. Investors reacted strongly, with shares rising 14.98% to $111.60 at the time of publication.

Third-quarter adjusted EPS of $1.90 beat the $1.88 estimate and sales of $2.063 billion beat $2.040 billion, with constant currency growth of 3.7% (4.7% excluding the China distributor consolidation). Knee business pressure and the timing of its recovery remain unresolved in the source.

The players

Zimmer Biomet

Zimmer Biomet is a major orthopedic medical device company known for hip, knee, and surgical technology products.

The details

Growth came from hips (up 7% globally), SET businesses (up 7.1% globally), and technology and data, bone cement and surgical (up 13%), with technology and data sales rising over 30% in the U.S. The Paragon 28 acquisition grew more than 18%, while the company's China distributor network consolidation weighed on reported growth.

Third quarter of fiscal 2026: Zimmer Biomet reported quarterly earnings and sales above estimates.
November 4, 2026: Shares hit a 52-week high following the earnings beat.
Fiscal 2026: The company raised full-year adjusted earnings and sales guidance.

Market Dynamics

The China distributor network consolidation strategy reduced reported growth by roughly one point, showing how restructuring in a major overseas market can temporarily weigh on results. Management's guidance raise suggests the company expects that drag to ease as its broader portfolio of hips, technology and data, and acquisitions continues to expand.

Investors holding Zimmer Biomet shares saw a sharp gain as results beat estimates and guidance rose. The raised outlook may be relevant to portfolio decisions, though the knee segment's ongoing pressure remains a factor to watch.

The takeaway

Strong performance in hips and technology offset knee weakness, and the upward guidance revision signals management's confidence in its growth trajectory heading into fiscal 2026.